Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 20, Issue 2, Pages e24-e34
http://dx.doi.org/10.1155/2009/658125
Review

Canadian Consensus Guidelines for the Optimal Use of Etravirine in the Treatment of HIV-Infected Adults

Marianne Harris,1 Jonathan B Angel,2 Jean-Guy Baril,3 Anita Rachlis,4 and Benoit Trottier5

1AIDS Research Program, St Paul’s Hospital, Vancouver, British Columbia, Canada
2Division of Infectious Diseases, Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
3Clinique médicale du Quartier latin, Centre hospitalier de l’université de Montréal, Université de Montréal, Montreal, Quebec, Canada
4Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
5Clinique médicale l’Actuel, Université de Montréal, Montreal, Quebec, Canada

Received 26 May 2008; Accepted 29 September 2008

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

BACKGROUND AND OBJECTIVES: A group of five Canadian physicians with significant experience in HIV management was convened. Their goal was to develop guidance specifically for Canadian HIV-treating physicians on the appropriate use of etravirine (TMC125, Intelence, Tibotec BVBA, Belgium) in adult HIV-infected patients.

METHODS: Evidence from the published literature, conference presentations and expert opinions of the group members were used to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, and from seven other physicians across Canada with clinical HIV treatment expertise and experience in the use of etravirine, as well as two Canadian scientists with HIV expertise. The final recommendations represent the core group’s consensus agreement, taking all feedback into consideration.

RESULTS AND CONCLUSIONS: The recommendations were developed to guide physicians in the optimal use of etravirine. The issues considered included HIV disease status, antiretroviral treatment history, drug resistance profiles, predictors of response to etravirine, background antiretroviral regimen and drug-drug interactions.